BPC January 10 update

Amarin AMRN shares rally 22% on buyout chatter

Price and Volume Movers

News flow has certainly dried up since Monday’s flood of news, with the conclusion of the J.P. Morgan Healthcare conference today. Expect the lack of news to continue through to tomorrow. We have just a couple items today.

Amarin Corporation plc (NASDAQ:AMRN) shares rallied to close up 22% to $18.35 on buyout rumors of the company. Online publication, StreetInsider, noted that Pfizer (NYSE: PFE) has shown an interest in acquiring the company and its cardiovascular treatment, Vascepa. Conversely, shares of Pfizer slipped 2.4% to $42.31. No comment was made by the respective companies.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for DEXTENZA to expand the current indication to include the treatment of ocular inflammation following ophthalmic surgery. 

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume

ADVANCERS:

PLx Pharma Inc. (PLXP): $4.53; +38%.

Novan, Inc. (NOVN): $1.70; +19%.

Oragenics, Inc. (OGEN): $1.05; +19%.

Mirati Therapeutics, Inc. (MRTX): $60.79; +13%.

TherapeuticsMD, Inc. (TXMD): $5.02; +13%.

DECLINERS:

Miragen Therapeutics, Inc. (MGEN): $3.53; -16%.

Regulus Therapeutics Inc. (RGLS): $1.10; -11%.

Atossa Genetics Inc. (ATOS): $1.43; -11%.

Vical Incorporated (VICL): $1.00; -10%.

Sophiris Bio, Inc. (SPHS): $1.05; -9%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

AGRX – Agile Therapeutics Inc.
Twirla
Contraceptive patch

PDUFA CRLs issued 2013 and 2017. New PDUFA date November 16, 2019.
$62.6 million

MGEN – Miragen Therapeutics Inc.
Cobomarsen MRG-106
Chronic Lymphocytic Leukemia (CLL); Diffuse Large B-Cell Lymphoma (DLBCL); Cutaneous T-cell Lymphoma (CTCL); Adult T-Cell Leukemia/Lymphoma (ATLL)

Phase 1 Phase 1 additional data presented April 26, 2019. Noted 4/5 patients remained stable for up to 16 months and continue on the trial.
$74.4 million

OCUL – Ocular Therapeutix Inc.
DEXTENZA
Post-surgical ocular inflammation and pain

PDUFA PDUFA date November 10, 2019.
$192.8 million